ROCKVILLE, Md., Sept. 29 /PRNewswire-FirstCall/ -- EntreMed, Inc. , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it has been named one of Maryland’s fastest growing companies in Deloitte’s Technology Fast 50 program. The program is presented by Deloitte and sponsored by Wilmer Cutler Pickering Hale and Dorr, NASDAQ and UK Trade & Investment, in association with media sponsors PR Newswire and Washington SmartCEO Magazine.
(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )
The Technology Fast 50 program is a ranking of the 50 fastest growing technology, media, telecommunications and life sciences companies throughout 16 regions in the United States and Canada. The Company has also been entered for consideration in the North American Technology Fast 500 program, a ranking of the 500 fastest growing technology, media, telecommunications and life sciences companies.
James S. Burns, EntreMed’s President and CEO, commented, “We are honored to receive this award and to be recognized by Deloitte as a notable life sciences growth company. EntreMed has focused its resources and scientific energies on the development of small molecule drugs that target the inhibition of multiple cellular pathways important in cancer and inflammatory diseases. Our recent progress has positioned us as a solid Phase 2 oncology drug development company with three clinical development programs. We look forward to continuing our progress on these programs.”
About EntreMed
EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in Phase 2 clinical trials for cancer, as well as in preclinical development for rheumatoid arthritis. MKC-1, an oral cell cycle regulator, is in Phase 2 studies for metastatic breast cancer. ENMD-1198, a novel tubulin binding agent, is also in Phase 1 studies in advanced cancers. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
About Deloitte
Deloitte refers to the one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms and their respective subsidiaries and affiliates. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other’s acts or omission. Each of the member firms is a separate and independent legal entity operating under the names of “Deloitte,” “Deloitte & Touche,” “Deloitte Touche Tohmatsu” or other related names. Services are provided by the member firms or their subsidiaries or affiliates and not by the Deloitte Touche Tohmatsu Verein. Deloitte & Touche USA LLP is the U.S. member firm of Deloitte Touche Tohmatsu. In the U.S., services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP and their subsidiaries), and not by Deloittee & Touche USA LLP.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications & Investor Relations of EntreMed, Inc., +1-240-864-2643.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comEntreMed, Inc.
CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643
Web site: http://www.entremed.com//
